Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of$ 1.69. This compares to earnings of $4.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 81.07%. A quarter ago, it was expected that this pharmaceutical company would post a loss of$ 1.79 per share when it actually produced a loss of $0.61, delivering a surprise of 65.92%.Over the last four quarters, ...